Eli Lilly and Company $LLY is Banque Transatlantique SA's 5th Largest Position

Key Points

• Banque Transatlantique SA increased its stake in Eli Lilly and Company by 47.4% in the first quarter, owning 203,737 shares worth approximately $155.50 million, making it the institution's fifth largest position.
• Eli Lilly reported quarterly earnings of $6.31 per share, exceeding estimates by $0.72, with revenue reaching $15.56 billion, marking a year-over-year increase of 37.6%.
• The company declared a quarterly dividend of $1.50 per share, payable on September 10th, reflecting an annualized yield of 0.8% and a payout ratio of 39.22%.

Banque Transatlantique SA grew its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 47.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 203,737 shares of the company's stock after buying an additional 65,507 shares during the period. Eli Lilly and Company accounts for about 2.9% of Banque Transatlantique SA's investment portfolio, making the stock its 5th largest position. Banque Transatlantique SA's holdings in Eli Lilly and Company were worth $155,502,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of the business. Alliancebernstein L.P. increased its position in Eli Lilly and Company by 7.9% in the first quarter. Alliancebernstein L.P. now owns 5,443,919 shares of the company's stock worth $4,496,187,000 after purchasing an additional 397,696 shares during the last quarter. Alyeska Investment Group L.P. bought a new stake in Eli Lilly and Company in the first quarter worth $2,523,000. Amundi increased its position in Eli Lilly and Company by 12.9% in the first quarter. Amundi now owns 4,953,128 shares of the company's stock worth $3,913,148,000 after purchasing an additional 564,307 shares during the last quarter. Aprio Wealth Management LLC increased its position in Eli Lilly and Company by 11.6% in the first quarter. Aprio Wealth Management LLC now owns 2,931 shares of the company's stock worth $2,421,000 after purchasing an additional 304 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. increased its position in Eli Lilly and Company by 1.3% in the first quarter. Adage Capital Partners GP L.L.C. now owns 741,722 shares of the company's stock worth $612,596,000 after purchasing an additional 9,172 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Activity

In related news, CEO David A. Ricks bought 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the purchase, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. This trade represents a 0.30% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction dated Tuesday, August 12th. The shares were bought at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director directly owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders bought 4,514 shares of company stock valued at $2,894,841. Insiders own 0.13% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on LLY shares. UBS Group reduced their price target on shares of Eli Lilly and Company from $1,050.00 to $895.00 and set a "buy" rating on the stock in a research report on Friday, August 8th. Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research report on Sunday, August 17th. Guggenheim cut their price objective on shares of Eli Lilly and Company from $942.00 to $875.00 and set a "buy" rating on the stock in a research report on Wednesday, August 13th. Erste Group Bank cut shares of Eli Lilly and Company from a "buy" rating to a "hold" rating in a research report on Thursday, June 5th. Finally, Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. One research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat, Eli Lilly and Company presently has an average rating of "Moderate Buy" and a consensus price target of $950.17.

Eli Lilly and Company Trading Down 2.2%

Shares of LLY traded down $16.56 during trading hours on Friday, reaching $726.35. 3,953,474 shares of the company traded hands, compared to its average volume of 5,282,453. The firm has a market cap of $687.46 billion, a price-to-earnings ratio of 47.47, a PEG ratio of 1.03 and a beta of 0.47. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $942.35. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock's fifty day moving average price is $743.84 and its 200 day moving average price is $781.81.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The firm had revenue of $15.56 billion during the quarter, compared to analyst estimates of $14.40 billion. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business's revenue was up 37.6% on a year-over-year basis. During the same period in the previous year, the firm earned $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 39.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.